Skip to main content

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Objective

Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in women), the lowest in Northern America (2.8 and 1.5, respectively). High mortality rates are also present in both sexes in Central and Eastern Europe, and in Central and South America.
None strategies have improved prognosis in locally advanced stage III and IV GC. Therefore, an urgent intervention is needed. Epidemiological and molecular features of GCs can vary widely according to their histological type, location and genetic makeup of the tumour. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori) and dietary factors. In particular, H. pylori infection plays a relevant role in GC incidence. Similarly, about 10% of GC patients are positive for the infection of the Epstein Barr Virus (EBV) . Most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU and CELAC countries is poorly known.
From a public health standpoint, prevention can be conducted at three levels: primary, secondary, and for improving outcomes at the advanced stage of disease. In recent years, the arrival of personalized medicine has revolutionized available treatments for cancer patients.
The primary aim of LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention: in EU and CELAC countries participating in this multicentre case-control study based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.

Field of science

  • /natural sciences/computer and information sciences/databases
  • /medical and health sciences/health sciences/public and environmental health
  • /social sciences/sociology/demography/mortality
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /natural sciences/biological sciences/genetics and heredity/genome
  • /medical and health sciences/health sciences/epidemiology

Call for proposal

H2020-SC1-2018-Single-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA
Address
Av Menendez Pelayo 4
46010 Valencia
Spain
Activity type
Research Organisations
EU contribution
€ 638 315

Participants (10)

Instituto Nacional de Cancerología
Mexico
EU contribution
€ 0
Address
Av. San Fernando 22
01480 Mexico
Activity type
Research Organisations
PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
Chile
EU contribution
€ 305 235
Address
Avenida Libertador Bernardo O'higgins 340
8331150 Santiago
Activity type
Higher or Secondary Education Establishments
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON
Spain
EU contribution
€ 550 000
Address
Calle Nazaret 115-117
08035 Barcelona
Activity type
Research Organisations
UNIVERSITAET LEIPZIG
Germany
EU contribution
€ 131 156,25
Address
Ritterstrasse 26
04109 Leipzig
Activity type
Higher or Secondary Education Establishments
EUROPEAN CANCER PATIENT COALITION
Belgium
EU contribution
€ 197 750
Address
Rue Montoyer 40
1000 Bruxelles
Activity type
Other
IPATIMUP - INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP
Portugal
EU contribution
€ 660 162,50
Address
Rua Julio Amaral De Carvalho 45
4200 135 Porto
Activity type
Research Organisations
CABALLERO LLANO CARMELO CESAR
Paraguay
EU contribution
€ 216 093,75
Address
Fortin Toledo 524 Apt 2
Asuncion
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ALEXANDER FLEMING SA
Argentina
EU contribution
€ 131 625
Address
Carmer 1180
C1426NZ Buenos Aires
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ANAXOMICS BIOTECH SL
Spain
EU contribution
€ 275 218,75
Address
Calle Diputacio 237, P 1 Pta 1
08007 Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
STICHTING VUMC
Netherlands
EU contribution
€ 471 875
Address
De Boelelaan 1117
1081 HV Amsterdam
Activity type
Research Organisations